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Abstract
Introduction: Shared decision making is not always commonplace in advanced colo‐
rectal	or	lung	cancer	care.	Decision	aids	(DAs)	might	be	helpful.	This	review	aimed	(a)	
to	provide	an	overview	of	DAs	for	patients	with	advanced	colorectal	or	lung	cancer	
and assess their availability; and (b) to assess their effectiveness if possible.
Methods: A	 systematic	 literature	 search	 (PubMed/EMBASE/PsycINFO/CINAHL)	
and	 Internet	 and	expert	 searches	were	carried	out	 to	 identify	 relevant	DAs.	Data	
from	the	DAs	included	were	extracted	and	the	quality	of	studies,	evidence	(Grading	
of	Recommendations	Assessment,	Development	and	Evaluation)	and	effectiveness	
(International	Patient	Decision	Aid	Standards)	of	DAs	were	determined.
Results: Ten	of	the	12	DAs	included	(four	colorectal	cancer,	four	lung	cancer	and	four	
generic)	are	still	available.	Most	(9/12)	were	applicable	throughout	the	disease	path‐
way	and	usable	for	all	decisions,	or	to	the	decision	for	supportive	care	with/without	
anti‐cancer	therapy.	Seven	studies	tested	effectiveness.	Effects	on	patient	outcomes	
varied,	but	were	generally	weakly	positive	(e.g.,	DAs	improved	patient	satisfaction)	
with	low	evidence.	Study	quality	was	fair	to	good.
Conclusion: There	is	a	lack	of	readily	available	DAs	that	have	been	demonstrated	to	
be effective in advanced colorectal or lung cancer. Rigorous testing of the effects of 
currently	available	and	future	DAs,	to	improve	patient	outcomes,	is	urgently	needed.
K E Y W O R D S
advanced	colorectal	cancer,	advanced	lung	cancer,	decision	aid,	shared	decision	making
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1  | INTRODUC TION
Colorectal and lung cancer are common types of cancer (new world‐
wide cases in 2018: 1.8 and 2.1 million respectively) with—depending 
on	the	tumour	stage—unfavourable	prognoses	(International	Agency	
for	Research	on	Cancer,	2018a,	2018b).	Patients	for	whom	curative	
treatment options are not or are no longer possible often face diffi‐
cult	and	preference‐sensitive	treatment	and/or	care	decisions	affect‐
ing	life	expectancy	and	quality	of	life.	Shared	decision	making	(SDM)	
can	help	make	these	decisions,	 including	decisions	to	forego	active	
cancer	treatment	(Legare,	Ratte,	Gravel,	&	Graham,	2008).
Shared decision making is an approach in which patients and cli‐
nicians	 discuss	 the	 best	 available	 evidence	when	 facing	 decisions,	
while patients are assisted in expressing their preferences and be‐
coming	 actively	 involved	 in	 decision	 making	 (Elwyn	 et	 al.,	 2012,	
2010;	Longtin	et	al.,	2010).	SDM	is	an	 important	element	of	high‐
quality	cancer	care,	with	essential	elements	including	acknowledg‐
ing	patients'	informed	values	(Stacey,	Samant,	&	Bennett,	2008)	and	
understanding	patients’	 care	goals	 (Bernacki	&	Block,	2014;	Kane,	
Halpern,	 Squiers,	 Treiman,	&	McCormack,	 2014).	 It	 is	 appreciated	
by	 many	 patients	 (Degner	 &	 Sloan,	 1992;	 Keating,	 Guadagnoli,	
Landrum,	 Borbas,	 &	Weeks,	 2002)	 and	 has	 been	 associated	 with	
positive	patient	outcomes,	such	as	increased	knowledge	about	the	
available	 options,	 better	 perceived	 quality	 of	 care	 and	 improved	
quality	of	life	(Kashaf	&	McGill,	2015;	Kehl	et	al.,	2015;	Stacey	et	al.,	
2017).	In	advanced	cancer,	decision	making	is	particularly	influenced	
by	personal	values	and	cannot	be	ruled	by	evidence‐based	medicine	
alone	(Bélanger,	Rodríguez,	&	Groleau,	2011;	Reyna,	Nelson,	Han,	&	
Pignone,	2015).	However,	despite	political	and	clinical	 support	 for	
the	SDM	approach,	uptake	in	clinical	practice	has	been	slow	(Brom	
et	al.,	2017;	Coulter,	Edwards,	Elwyn,&	Thomson,2011).
For	enhancing	the	process	of	actively	involving	patients	in	SDM,	
using	decision	aids	(DAs)	might	be	helpful	(van	Weert	et	al.,	2016).	
DAs	 are	 tools	 that	 help	 patients	 to	 come	 to	 the	 best	 decision	 by	
showing	the	available	options	(treatment	and	care	options),	clarify‐
ing personal values and providing information about the available 
options	 and	 their	 outcomes	 (Waitzkin,	 1985).	DAs	 are	 available	 in	
various	forms	such	as	patient	letters,	video	or	audiotapes,	 leaflets,	
computer	programs	or	interactive	media	(Stacey	et	al.,	2014).	In	es‐
sence,	they	encourage	patients	to	think	about	their	preferences	for	
future	treatment	and	care.	Exploring	options	using	DAs	helps	cancer	
patients	 form	more	 stable	 preferences	 (Pieterse	 et	 al.,	 2011),	 im‐
proves	their	knowledge	and	awareness	of	treatment	options	(Austin,	
Mohottige,	 Sudore,	 Smith,	 &	Hanson,	 2015),	 enhances	 patient	 in‐
volvement	in	decision	making	(Kashaf	&	McGill,	2015;	Kunneman	et	
al.,	2015;	Stacey	et	al.,	2008)	and	improves	quality‐of‐life	outcomes	
(Bernacki	&	Block,	2014;	Kashaf	&	McGill,	2015).
Decision aids might be promising for advanced colorectal and 
lung	patients	who	face	difficult	and	preference‐sensitive	treatment	
decisions,	a	group	that	is	growing	(Cronin	et	al.,	2018).	There	are	no	
overviews	of	which	DAs	are	available	for	these	patients	and	whether	
these	DAs	affect	patient	outcomes.	This	review	therefore	aims	(a)	to	
provide	an	overview	of	DAs	for	patients	with	advanced	colorectal	
or lung cancer and assess their availability; and (b) to assess their 
effectiveness if possible.
2  | METHODS
This systematic review was conducted and reported in line with the 
PRISMA	Statement	(Moher,	Liberati,	Tetzlaff,	&	Altman,	2009)	and	
registered	 in	PROSPERO	(ID	=	CRD42018094453).	Two	strategies	
were	used	to	identify	DAs	for	patients	with	advanced	colorectal	or	
lung cancer: (a) a systematic literature search; (b) an Internet search 
and expert consultation.
2.1 | Search strategy
2.1.1 | Systematic literature search
PubMed,	EMBASE,	PsycINFO	and	CINAHL	were	searched	to	iden‐
tify	 relevant	 articles	 published	between	 January	2006	 and	March	
2018	(comparable	to	what	was	done	by	Spronk,	Burgers,	Schellevis	
van	Vliet,	and	Korevaar	(2018)).	We	used	this	timeframe	because	we	
were	looking	for	DAs	that	are	still	relevant.	Older	DAs	that	are	still	
relevant would have been found through the Internet search and 
when	consulting	the	experts,	or	through	manual	searching	of	refer‐
ence	 lists.	The	search	strategy	(Appendix	1)	was	developed	in	col‐
laboration with an experienced librarian and checked by an expert in 
the	field	(Glyn	Elwyn).	A	manual	search	of	reference	lists	of	the	arti‐
cles included was conducted to identify additional relevant articles.
2.1.2 | Internet search and consultation of experts
The Internet search and expert consultation complemented the sys‐
tematic	 literature	 search,	 as	we	hypothesised	 that	not	all	 the	DAs	
might	 have	 been	 published	 in	 peer‐reviewed	 journals	 (or	 not	 yet).	
Internet searches covering the topics “advanced colorectal or lung 
cancer”	and	“decision	making”	were	carried	out	in	Google	(Appendix	
2)	in	2018	on	the	21st	of	March	and	the	first	four	pages	of	results	
were	screened	(comparable	to	what	was	done	by	Van	Vliet,	Harding,	
Bausewein,	Payne,	and	Higginson	(2015)).	 In	addition,	websites	 in‐
cluding	overviews	of	DAs	(http://www.med‐decs.org/,	https	://decis	
ionaid.ohri.ca/)	were	screened	on	the	same	day.	Lastly,	experts	were	
contacted	by	e‐mail	to	 identify	available	DAs	for	patients	with	ad‐
vanced	colorectal	or	 lung	cancer.	Experts	were	 international	SDM	
experts (n	=	6,	from	Australia,	Canada,	Norway,	the	United	Kingdom	
and	 the	USA)	 and	Dutch	 SDM,	 colorectal	 cancer	 and	 lung	 cancer	
experts (n	=	13).	They	were	identified	via	core	articles	or	through	the	
research team's own network.
2.2 | Inclusion criteria
2.2.1 | Systematic literature search
We	defined	our	research	question	according	to	the	PICO	criteria:
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Original	 empirical	 published	 studies,	 written	 in	 any	 language,	
were included if they focused on:
Participants: adult (>18 years) patients with advanced colorectal or 
lung	cancer	(i.e.,	patients	for	whom	curative	treatment	options	are	
no longer possible).
Intervention:	development	and/or	evaluation	of	a	DA	that	focused	
on (a) providing information about current options; (b) current de‐
cision making processes; or (c) helping patients by eliciting prefer‐
ences for current treatment options.
Comparison:	for	our	second	research	question,	that	is	the	effective‐
ness	 of	DAs,	 studies	were	 included	 if	 they	 included	 a	 compari‐
son	(e.g.,	standard	care)	and	also	when	there	was	no	comparison	
group	(e.g.,	pre‐test,	post‐test	design).
Outcomes:	for	our	second	research	question,	that	is	the	effective‐
ness	of	DAs,	any	patient‐reported	outcome	(e.g.,	satisfaction	with	
decision)	and/or	health	outcomes	(e.g.,	general	health).
2.2.2 | Internet search and consultation of experts
The same patient and intervention inclusion criteria were applied as 
for	 the	 systematic	 literature	 search.	However,	we	anticipated	 that	
the comparison and outcome inclusion criteria would not apply.
2.3 | Study selection and data extraction
2.3.1 | Systematic literature search
One researcher (IS) performed the search and removed duplicates. 
Two	researchers	(IS	and	LvV)	independently	screened	15%	of	the	re‐
cords	based	on	title	and	abstract.	The	overlap	was	100%,	so	the	ad‐
ditional records were screened by a single researcher (IS). In the case 
of	any	doubt,	the	record	was	included	and	screened	by	two	authors	
independently	during	full‐text	screening.	Full‐text	screening	and	ex‐
traction of data was done independently by two researchers (IS and 
MH/MM).	 The	 information	 extracted	 included	 study	 characteristics	
(first	author,	year	of	publication,	study	size,	study	design,	patient	char‐
acteristics,	outcome	measures	[if	present]),	characteristics	of	the	DA	
(name,	description,	target	population,	country,	options	on	which	the	
DA	focuses),	and	patient‐reported	outcomes	and	health	outcomes	(if	
present).	 In	the	case	where	a	DA	was	not	 included	 in	the	article,	or	
not	 found	 on	 the	 Internet,	 the	 authors/developers	were	 contacted	
about	its	status	and	asked	to	send	the	researchers	a	copy	of	the	DA.	
Disagreements arising from decisions around article inclusion or the 
extraction	of	data	were	discussed	with	a	third	researcher	(LvV).	When	
consensus	was	not	reached	with	the	third	author,	the	research	team	
was involved and the issue was discussed until consensus was reached.
2.3.2 | Internet search and consultation of experts
The Internet search was carried out by one researcher (IS). Potentially 
relevant	 DAs	 were	 selected	 and	 independently	 screened	 by	 two	
researchers	 (IS	 and	MH/LvV).	 DAs	 provided	 by	 the	 experts	 were	
handled in the same way. The data extraction followed the same 
steps as used in the systematic literature search.
2.4 | Quality assessment
2.4.1 | Quality of included studies
As	 the	 included	 studies	 used	 different	 designs,	 their	 quality	 was	
assessed	with	the	quality	assessment	 tool	of	Hawker,	Payne,	Kerr,	
Hardey,	and	Powell	(2002).	This	tool	includes	nine	domains:	abstract	
and title; introduction and aims; method and data; sampling; data 
analysis; ethics and bias; results; transferability and implications/
usefulness.	 Following	 Hawker	 et	 al.	 (2002),	 each	 domain	 was	 as‐
sessed	for	each	study,	with	scores	ranging	from	1	(“very	poor”)	to	4	
(“good”). The total score ranges between 9 and 36 points. Scores up 
to	18	points	are	rated	as	“poor	quality”;	scores	between	19	and	27	as	
“fair	quality”;	scores	above	27	as	“good	quality”	(Appendix	3).	Each	
study	was	independently	assessed	by	two	researchers	(MH	and	AF/
SvD).	A	threshold	of	five	points	was	used;	if	the	overall	quality	scores	
differed	more	than	five	points,	the	average	was	calculated	(compara‐
ble	to	the	way	it	was	done	by	Voss	et	al.	(2017).
2.4.2 | Level of evidence DAs included
To	 assess	 the	 level	 of	 evidence	 of	 the	 DAs,	 the	 Grading	 of	
Recommendations	 Assessment,	 Development	 and	 Evaluation	
(GRADE)	methodology	was	used	(Guyatt	et	al.,	2008).	GRADE	clas‐
sifies	evidence	into	four	quality	levels	(high,	moderate,	low	and	very	
low). Studies were classified based on their design. Randomised 
control	 trials	 (RCTs)	 get	 a	 high‐quality	 initial	 grade	 and	 observa‐
tional	studies	a	low‐quality	initial	grade.	These	initial	grades	can	be	
upgraded or downgraded after assessment of their strengths and 
weaknesses.	Risk	of	bias,	indirectness	of	evidence,	inconsistency	of	
results,	imprecision	in	the	results	and	publication	bias	are	criteria	for	
downgrading,	whereas	a	large	magnitude	of	effect,	dose–response	
and opposing residual confounding or bias are criteria for upgrad‐
ing.	Based	on	the	upgrading	and	downgrading	criteria,	the	final	evi‐
dence grade was independently determined by two researchers (IS 
and	MH).	Disagreements	were	 resolved	by	discussion	with	a	 third	
researcher	(LvV).
2.4.3 | Effectiveness of the DAs included
To	 evaluate	 the	 effectiveness	 of	 the	 DAs,	 “part	 III	 Effectiveness”	
of	the	International	Patient	Decision	Aid	Standards	(IPDAS)	criteria	
for	judging	the	quality	of	patient	DAs	was	used	(Elwyn	et	al.,	2006).	
This part consists of seven items. These items include assessment 
of	whether	 the	DA	 helps	 patients	 (a)	 to	 recognise	 that	 a	 decision	
needs to be made; (b) to know the options and their features; (c) 
to understand that values affect the decision; (d) to be clear about 
which features of the options matter most; (e) to discuss values with 
their	practitioner,	6)	 to	become	 involved	 in	 the	patients’	preferred	
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way; and (g) to improve the match between the chosen option and 
the features that matter most to the properly informed patient. If 
an	item	is	fulfilled,	a	score	of	1	is	given.	Total	scores	could	range	be‐
tween	0	and	7	points.	Two	researchers	(IS	and	MM)	independently	
scored	the	IPDAS.	Disagreements	were	resolved	by	discussion	with	
a	third	researcher	(LvV).
3  | RESULTS
The	initial	literature	search	resulted	in	1,438	potentially	relevant	ar‐
ticles.	After	removal	of	duplicates	and	elimination	of	articles	based	
on	title	abstract	screening,	the	full	texts	of	23	articles	were	screened.	
Thirteen	of	these	did	not	meet	our	inclusion	criteria,	resulting	in	the	
inclusion	of	10	articles	describing	eight	unique	DAs	(Figure	1).	The	
Internet	 search	 revealed	 two	 relevant	 DAs	 and	 the	 experts	 sug‐
gested	six	DAs.	Four	of	these	eight	DAs	had	not	been	identified	by	
the systematic search and were therefore added (Figure 1).
Table	1	gives	an	overview	of	the	main	characteristics	of	all	DAs	
(n	 =	 12)	 that	were	 included.	 Four	DAs	were	 specifically	 designed	
for	patients	with	advanced	colorectal	cancer	(Enzinger	et	al.,	2017;	
Leighl	et	al.,	2011;	Maag	Lever	Darm	Stichting	(Dutch	digestive	dis‐
ease	foundation),	2016;	Oostendorp	et	al.,	2017),	four	were	designed	
for	 advanced	 lung	 cancer	 patients	 (DuBenske,	 Gustafson,	 Shaw,	
&	 Cleary,	 2010;	 MAASTRO	 clinic,	 2018;	 Steendam,	 Schaffelaars,	
Belderbos,	&	Pruyn,	2016;	Tang	et	al.,	2008)	and	the	other	four	were	
not	disease‐specific	(Henselmans	et	al.,	2018;	Meropol	et	al.,	2013;	
Shirai	et	al.,	2012;	Smith	et	al.,	2011).	Five	had	been	developed	in	the	
Netherlands,	 four	 in	the	USA,	one	 in	Singapore,	one	 in	Japan,	and	
one	was	developed	by	collaborating	researchers	from	both	Australia	
and	Canada.	All	the	DAs	had	been	developed	to	be	used	by	patients	
before the consultation; none were designed to be used during the 
consultation.	Only	one	DA	(Meropol	et	al.,	2013)	engaged	the	clini‐
cian,	who	received	a	summary	report	of	the	patient's	responses	that	
could then be used during the consultation.
3.1 | Colorectal cancer DAs
All	 four	 of	 the	 DAs	 for	 patients	 with	 advanced	 colorectal	 cancer	
are	 still	 available.	 Two	 DAs	 included	 booklets	 presenting	 options	
for	 supportive	 care	 with	 or	 without	 first‐line	 (Leighl	 et	 al.,	 2011)	
or	 second‐line	 (Oostendorp	 et	 al.,	 2017)	 chemotherapy	 (Table	 1).	
The	booklet	of	Leighl	et	al.	was	accompanied	by	an	audiotape.	The	
third	DA,	a	booklet	accompanied	by	a	video,	included	the	informed	
consent	process	regarding	palliative	chemotherapy	(Enzinger	et	al.,	
2017),	 and	 the	 fourth	DA	 (Decision	aid	MLDS)	 (Maag	Lever	Darm	
Stichting	 (Dutch	 digestive	 disease	 foundation),	 2016)	 is	 a	 website	
(including videos) about patients’ value clarification in the palliative 
phase of their disease.
The	effectiveness	of	two	DAs	focusing	on	supportive	care	with	or	
without	first‐	or	second‐line	chemotherapy	was	tested	by	comparing	
them	in	RCTs	against	standard	care	(Leighl	et	al.,	2011;	Oostendorp	
et	 al.,	 2017)	 (Table	2).	 Patients	 receiving	 the	DA	on	 first‐line	 che‐
motherapy	(Leighl	et	al.,	2011)	demonstrated	higher	overall	under‐
standing of the prognoses but satisfaction was similar to the control 
group	 (quality:	 good,	GRADE:	moderate,	 IPDAS:	6/7).	Patients	 re‐
ceiving	 the	 DA	 on	 second‐line	 chemotherapy	 (Oostendorp	 et	 al.,	
2017)	were	no	less	anxious	and	did	not	perceive	better	well‐being	
compared	 to	 the	 control	 group	 (quality:	 good,	GRADE:	moderate,	
IPDAS:	3/7).	A	 third	DA	 (Enzinger	et	 al.,	 2017)	was	developed	 for	
F I G U R E  1   Flow chart of the inclusion 
of	decision	aids	(DAs)
     |  5 of 14SPRONK et al.
T
A
B
L
E
 1
 
O
ve
rv
ie
w
	o
f	D
A
s	
fo
r	
sh
ar
ed
	d
ec
is
io
n	
m
ak
in
g	
in
	a
dv
an
ce
d	
co
lo
re
ct
al
	a
nd
	lu
ng
	c
an
ce
r
N
am
e 
de
ci
si
on
 a
id
/s
ho
rt
 
de
sc
rip
tio
n
Fi
rs
t a
ut
ho
r/
de
ve
lo
pe
r
Ye
ar
 
de
ve
lo
pe
d
Co
un
tr
y
So
ur
ce
D
es
cr
ip
tio
n 
of
 to
ol
C
ol
or
ec
ta
l c
an
ce
r
D
ec
is
io
n	
ai
d	
fo
r	
se
co
nd
‐l
in
e	
ch
em
ot
he
ra
py
O
os
te
nd
or
p 
(O
os
te
nd
or
p 
et
 
al
.,	
20
17
)
20
17
N
et
he
rla
nd
s
E,
	I,
	S
A
	D
A
	(b
oo
kl
et
)	d
es
cr
ib
in
g	
th
e	
ad
ve
rs
e	
ev
en
ts
,	r
es
po
ns
e	
of
	t
he
	c
an
ce
r	
an
d	
su
rv
iv
al
	o
f	s
up
po
rt
iv
e	
ca
re
	
w
it
h	
or
	w
it
ho
ut
	s
ec
on
d‐
lin
e	
pa
lli
at
iv
e	
ch
em
ot
he
ra
py
D
ec
is
io
n	
ai
d	
fo
r	
fi
rs
t‐
lin
e	
ch
em
ot
he
ra
py
Le
ig
hl
	(L
ei
gh
l	e
t	
al
.,	
20
11
)
20
11
A
us
tr
al
ia
	a
nd
	
C
an
ad
a
E,
	S
A
	D
A
	(b
oo
kl
et
	w
it
h	
ac
co
m
pa
ny
in
g	
au
di
ot
ap
e)
	p
re
se
nt
in
g	
op
ti
on
s	
of
	s
up
po
rt
iv
e	
ca
re
,	w
it
h	
or
	w
it
ho
ut
	
ch
em
ot
he
ra
py
.	P
ot
en
ti
al
	b
en
ef
it
s	
an
d	
si
de
	e
ff
ec
ts
	o
f	d
if
fe
re
nt
	c
he
m
ot
he
ra
py
	r
eg
im
en
s,
	a
nd
	e
vi
de
nc
e‐
ba
se
d	
pr
og
no
st
ic
	e
st
im
at
es
	a
re
	d
es
cr
ib
ed
,	a
nd
	a
	v
al
ue
	c
la
ri
fi
ca
ti
on
	e
xe
rc
is
e	
is
	in
cl
ud
ed
A
	p
ro
to
ty
pe
	v
id
eo
	a
nd
	c
om
‐
pa
ni
on
 b
oo
kl
et
 s
up
po
rt
in
g 
in
fo
rm
ed
 c
on
se
nt
En
zi
ge
r	
(E
nz
in
ge
r	
et
	a
l.,
	2
01
7
)
20
17
U
SA
S
A
	p
ro
to
ty
pe
	(r
eg
im
en
‐s
pe
ci
fi
c	
ch
em
ot
he
ra
py
	in
fo
rm
ed
	c
on
se
nt
)	v
id
eo
	a
nd
	c
om
pa
ni
on
	b
oo
kl
et
	(e
xp
la
in
‐
in
g	
gu
id
el
in
e‐
re
co
m
m
en
de
d	
tr
ea
tm
en
t	
op
ti
on
s	
fo
r	
m
et
as
ta
ti
c	
co
lo
re
ct
al
	c
an
ce
r)
	s
up
po
rt
in
g	
in
fo
rm
ed
	
co
ns
en
t f
or
 a
 c
om
m
on
 p
al
lia
tiv
e 
ch
em
ot
he
ra
py
 re
gi
m
en
M
LD
S	
de
ci
si
on
	a
id
M
LD
S	
(M
aa
g	
Le
ve
r	
D
ar
m
	
St
ic
ht
in
g 
(D
ut
ch
 d
ig
es
tiv
e 
di
se
as
e	
fo
un
da
ti
on
),	
20
16
)
20
16
N
et
he
rla
nd
s
E,
	I
W
eb
si
te
 p
ro
vi
di
ng
 in
fo
rm
at
io
n 
(in
cl
ud
in
g 
vi
de
os
) a
nd
 a
n 
in
st
ru
m
en
t f
or
 p
at
ie
nt
’s 
va
lu
e 
cl
ar
ifi
ca
tio
n 
of
 
w
hi
ch
 a
 s
um
m
ar
y 
is
 m
ad
e 
to
 d
is
cu
ss
 w
ith
 th
e 
ph
ys
ic
ia
n.
Lu
ng
	c
an
ce
r
M
aa
st
ro
	d
ec
is
io
n	
ai
d
M
A
A
ST
R
O
	c
lin
ic
	(M
A
A
ST
R
O
	
cl
in
ic
,	2
01
8)
20
18
N
et
he
rla
nd
s
E
A
	D
A
	(w
eb
si
te
)	f
or
	lu
ng
	c
an
ce
r	
pa
ti
en
ts
	(s
ta
ge
),	
th
at
	d
es
cr
ib
es
	c
ha
ra
ct
er
is
ti
cs
,	s
id
e	
ef
fe
ct
s	
an
d	
di
ff
er
‐
en
ce
s	
be
tw
ee
n	
su
rg
er
y	
an
d	
ra
di
ot
he
ra
py
,	a
nd
	a
ss
is
ts
	p
at
ie
nt
s	
to
	t
hi
nk
	a
bo
ut
	t
he
ir
	p
re
fe
re
nc
es
	a
nd
	
va
lu
es
 s
o 
th
ey
 c
an
 d
is
cu
ss
 th
ei
r p
re
fe
re
nc
es
 w
ith
 th
ei
r c
lin
ic
ia
n 
an
d 
m
ak
e 
an
 in
fo
rm
ed
 d
ec
is
io
n
D
ec
is
io
n 
bo
ar
d
Ta
ng
	(T
an
g	
et
	a
l.,
	2
0
0
8)
20
08
Si
ng
ap
or
e
S
A
	d
ec
is
io
n	
bo
ar
d	
ou
tl
in
in
g	
th
e	
va
ri
ou
s	
ad
va
nt
ag
es
	a
nd
	d
is
ad
va
nt
ag
es
	o
f	F
x	
sc
he
du
le
s	
(1
7	
G
y	
in
	t
w
o	
fr
ac
ti
on
s	
vs
.	3
9	
G
y	
in
	1
3	
fr
ac
ti
on
s)
,	i
n	
th
e	
pa
lli
at
io
n	
of
	s
ym
pt
om
at
ic
	u
nr
es
ec
ta
bl
e	
lu
ng
	c
an
ce
r
D
ec
is
io
n	
A
id
	f
or
	s
ta
ge
	4
	lu
ng
	
ca
nc
er
St
ee
nd
am
	(S
te
en
da
m
	e
t	
al
.,	
20
16
)
20
16
N
et
he
rla
nd
s
E
A
	t
oo
l	f
or
	p
at
ie
nt
s	
w
it
h	
ad
va
nc
ed
	lu
ng
	c
an
ce
r	
an
d	
th
ei
r	
re
la
ti
ve
s,
	w
hi
ch
	in
cl
ud
es
	a
n	
in
tr
od
uc
to
ry
	le
tt
er
,	
pr
es
en
ta
ti
on
	o
f	p
ot
en
ti
al
	p
ro
s	
an
d	
co
ns
	o
f	t
he
	t
re
at
m
en
t	
op
ti
on
s	
(p
al
lia
ti
ve
	c
he
m
o,
	im
m
un
ot
he
ra
py
,	o
r	
ex
pe
ri
m
en
ta
l	t
re
at
m
en
t	
or
	s
up
po
rt
iv
e	
ca
re
),	
m
os
t	
co
m
m
on
	s
id
e	
ef
fe
ct
s,
	a
nd
	a
	p
er
so
na
l	D
A
	f
or
	m
ak
in
g	
di
ff
ic
ul
t d
ec
is
io
ns
Co
m
pr
eh
en
siv
e 
H
ea
lth
 
En
ha
nc
em
en
t S
up
po
rt
 S
ys
te
m
 
(C
H
ES
S)
a
D
uB
en
sk
e 
(D
uB
en
sk
e	
et
	a
l.,
	
20
10
)
20
10
U
SA
S
A 
W
eb
‐b
as
ed
 in
te
ra
ct
iv
e 
he
al
th
 c
om
m
un
ic
at
io
n 
sy
st
em
 (I
H
CS
)—
(C
H
ES
S)
—
fo
r p
at
ie
nt
s w
ith
 a
dv
an
ce
d 
lu
ng
 
ca
nc
er
 a
nd
 th
ei
r f
am
ily
 c
ar
eg
iv
er
s, 
w
hi
ch
 p
ro
vi
de
s i
nf
or
m
at
io
n,
 c
om
m
un
ic
at
io
n,
 a
nd
 c
oa
ch
in
g 
re
so
ur
ce
s a
s 
w
el
l a
s a
 sy
m
pt
om
 tr
ac
ki
ng
 sy
st
em
 th
at
 re
po
rt
s h
ea
lth
 st
at
us
 to
 th
e 
cl
in
ic
al
 te
am
N
ot
 c
ol
or
ec
ta
l o
r l
un
g 
ca
nc
er
 s
pe
ci
fic
Q
ue
st
io
n 
pr
om
pt
 s
he
et
 (Q
PS
)
Sh
ir
ai
	(S
hi
ra
i	e
t	
al
.,	
20
12
)
20
12
Ja
pa
n
S
A
	q
ue
st
io
n	
pr
om
pt
	s
he
et
	(6
3	
qu
es
ti
on
s)
	t
o	
fa
ci
lit
at
e	
th
e	
in
vo
lv
em
en
t	
(b
y	
pr
ep
ar
in
g	
qu
es
ti
on
s	
pr
io
r	
to
	
co
ns
ul
ta
tio
n)
 o
f a
dv
an
ce
d 
ca
nc
er
 p
at
ie
nt
s 
du
rin
g 
co
ns
ul
ta
tio
ns
C
on
su
lt
at
io
n	
gu
id
e	
C
H
O
IC
E
H
en
se
lm
an
s 
(H
en
se
lm
an
s 
et
 
al
.,	
20
18
)
20
16
N
et
he
rla
nd
s
E
A
	b
oo
kl
et
	w
it
h	
sa
m
pl
e	
qu
es
ti
on
s	
to
	f
ac
ili
ta
te
	s
ha
re
d	
de
ci
si
on
	m
ak
in
g	
an
d	
an
	in
st
ru
m
en
t	
fo
r	
va
lu
e	
cl
ar
ifi
ca
tio
n
D
ec
is
io
n	
ai
d	
fo
r	
fi
rs
t‐
,	s
ec
‐
on
d‐
,	t
hi
rd
‐	
an
d	
fo
ur
th
‐l
in
e	
ch
em
ot
he
ra
py
Sm
it
h	
(S
m
it
h	
et
	a
l.,
	2
01
1)
20
13
U
SA
S
St
at
e‐
of
‐t
he
‐a
rt
	t
ab
le
s	
w
it
h	
in
fo
rm
at
io
n	
fo
r	
pa
ti
en
ts
	w
it
h	
ad
va
nc
ed
	b
re
as
t,
	lu
ng
,	c
ol
on
	a
nd
	h
or
m
on
e‐
re
fr
ac
to
ry
	p
ro
st
at
e	
ca
nc
er
s	
fa
ci
ng
	f
ir
st
‐,	
se
co
nd
‐,	
th
ir
d‐
	a
nd
	f
ou
rt
h‐
lin
e	
ch
em
ot
he
ra
py
.
CO
N
N
EC
T
M
er
op
ol
 (M
er
op
ol
	e
t	
al
.,	
20
13
)
20
13
U
SA
S
A 
co
m
m
un
ic
at
io
n 
ai
d 
th
at
 a
ss
es
se
s p
at
ie
nt
 v
al
ue
s (
qu
al
ity
 o
f l
ife
), 
go
al
s, 
an
d 
co
m
m
un
ic
at
io
n 
pr
ef
er
en
ce
s, 
an
d 
in
cl
ud
es
 c
om
m
un
ic
at
io
n 
sk
ill
s t
ra
in
in
g,
 p
lu
s a
 p
re
‐c
on
su
lta
tio
n 
su
m
m
ar
y 
re
po
rt
 to
 th
e 
ph
ys
ic
ia
n
N
ot
e:
 T
oo
ls
 th
at
 a
re
 n
o 
lo
ng
er
 a
va
ila
bl
e 
ar
e 
pr
in
te
d 
in
 it
al
ic
s.
So
ur
ce
:	S
	=
	s
ys
te
m
at
ic
	s
ea
rc
h,
	E
	=
	e
xp
er
ts
,	I
	=
	In
te
rn
et
	s
ea
rc
h,
	D
A
	=
	d
ec
is
io
n	
ai
d.
6 of 14  |     SPRONK et al.
T
A
B
L
E
 2
 
C
ha
ra
ct
er
is
ti
cs
	o
f	e
va
lu
at
ed
	d
ec
is
io
n	
ai
ds
	(D
A
s)
,	i
nc
lu
di
ng
	t
he
	q
ua
lit
y,
	G
ra
di
ng
	o
f	R
ec
om
m
en
da
ti
on
s	
A
ss
es
sm
en
t,
	D
ev
el
op
m
en
t	
an
d	
Ev
al
ua
ti
on
	(G
R
A
D
E)
	a
nd
	In
te
rn
at
io
na
l	P
at
ie
nt
	
D
ec
is
io
n	
A
id
	S
ta
nd
ar
ds
	(I
PD
A
S)
	s
co
re
s
N
am
e 
of
 d
ec
i-
si
on
 a
id
/s
ho
rt
 
de
sc
rip
tio
n
Fi
rs
t a
ut
ho
r 
(y
ea
r)
St
ud
y 
po
pu
la
tio
n 
n 
(s
ex
), 
ag
e
D
es
ig
n
D
ec
is
io
n 
ai
d 
ou
tc
om
e 
m
ea
su
re
s
O
ut
co
m
e
Q
ua
lit
ya
G
R
A
D
E
IP
D
A
S
C
ol
or
ec
ta
l c
an
ce
r
D
ec
is
io
n 
ai
d 
fo
r 
se
co
nd
‐l
in
e	
ch
em
ot
he
ra
py
O
os
te
nd
or
p 
(2
01
7)
 
(O
os
te
nd
or
p 
et
	a
l.,
	2
01
7
)
Pa
tie
nt
s 
w
ith
 m
et
a‐
st
at
ic
 c
ol
or
ec
ta
l 
or
	b
re
as
t	
ca
nc
er
,	
n	
=	
12
8	
(F
:	6
3%
),	
m
ea
n 
ag
e:
 6
1 
ye
ar
s
RC
T
P
ri
m
ar
y:
	(w
el
l‐
be
in
g)
	a
nx
ie
ty
 
Se
co
nd
ar
y:
	(w
el
l‐
be
in
g)
	d
ep
re
s‐
si
on
,	g
en
er
al
	h
ea
lt
h,
	c
an
ce
r	
w
or
‐
ri
es
,	h
ea
lt
h‐
re
la
te
d	
qu
al
it
y	
of
	li
fe
 
A
dd
it
io
na
l:	
co
pi
ng
	s
ty
le
s,
	a
m
ou
nt
	
of
	in
fo
rm
at
io
n	
re
ce
iv
ed
,	s
at
is
fa
c‐
ti
on
	w
it
h	
th
e	
qu
al
it
y	
of
	in
fo
r‐
m
at
io
n,
	s
ub
je
ct
iv
e	
kn
ow
le
dg
e,
	
tr
ea
tm
en
t	
pr
ef
er
en
ce
,	d
ec
is
io
n	
sa
ti
sf
ac
ti
on
	a
nd
	u
nc
er
ta
in
ty
,	
de
ci
si
on
 c
on
tr
ol
 a
nd
 tr
ea
tm
en
t 
at
tit
ud
es
N
o 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t d
iff
er
en
ce
s 
in
 a
nx
ie
ty
 
N
o 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t d
iff
er
en
ce
s 
in
 d
ep
re
s‐
si
on
,	g
en
er
al
	h
ea
lt
h,
	c
an
ce
r	
w
or
ri
es
,	h
ea
lt
h‐
re
la
te
d	
qu
al
it
y	
of
	li
fe
 
U
se
	o
f	t
he
	D
A
	w
as
	a
ss
oc
ia
te
d	
w
it
h	
st
ro
ng
er
	t
re
at
‐
m
en
t p
re
fe
re
nc
es
 (p
	=
	0
.0
3
0)
	a
nd
	in
cr
ea
se
d	
su
bj
ec
‐
tiv
e 
kn
ow
le
dg
e 
(p
	=
	0
.0
22
) 
N
o 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t d
iff
er
en
ce
s 
in
 c
op
in
g 
st
yl
es
,	a
m
ou
nt
	o
f	i
nf
or
m
at
io
n	
re
ce
iv
ed
,	s
at
is
fa
ct
io
n	
w
it
h	
qu
al
it
y	
of
	in
fo
rm
at
io
n,
	d
ec
is
io
n	
sa
ti
sf
ac
ti
on
	
an
d	
un
ce
rt
ai
nt
y,
	d
ec
is
io
n	
co
nt
ro
l	a
nd
	t
re
at
m
en
t	
at
tit
ud
es
G
oo
d
M
od
er
at
e
3
D
ec
is
io
n 
ai
d 
fo
r	
fi
rs
t‐
lin
e	
ch
em
ot
he
ra
py
Le
ig
hl
	(2
01
1)
	
(L
ei
gh
l	e
t	
al
.,	
20
11
)
Pa
tie
nt
s 
w
ith
 a
d‐
va
nc
ed
 c
ol
or
ec
ta
l 
ca
nc
er
,	n
	=
	2
0
8	
(F
:	
46
%
),	
m
ed
ia
n	
ag
e:
	
61
 y
ea
rs
RC
T
Pr
im
ar
y:
 p
at
ie
nt
 u
nd
er
st
an
di
ng
 o
f 
pr
og
no
st
ic
 a
nd
 tr
ea
tm
en
t i
nf
or
m
a‐
tio
n 
an
d 
sa
tis
fa
ct
io
n 
w
ith
 d
ec
is
io
n 
m
ak
in
g 
A
dd
it
io
na
l:	
de
ci
si
on
al
	c
on
fl
ic
t,
	
an
xi
et
y,
	q
ua
lit
y	
of
	li
fe
,	t
re
at
m
en
t	
de
ci
si
on
	m
ad
e,
	p
at
ie
nt
	a
ch
ie
ve
‐
m
en
t o
f d
ec
is
io
n 
in
vo
lv
em
en
t 
pr
ef
er
en
ce
s
P
at
ie
nt
s	
re
ce
iv
in
g	
th
e	
D
A
	d
em
on
st
ra
te
d	
a	
gr
ea
te
r	
in
cr
ea
se
 in
 u
nd
er
st
an
di
ng
 o
f p
ro
gn
os
is
 a
nd
 th
e 
pa
lli
at
iv
e	
go
al
s	
of
	t
re
at
m
en
t,
	w
it
h	
hi
gh
er
	o
ve
ra
ll	
un
de
rs
ta
nd
in
g 
(p
	=
	0
.0
01
) 
N
o 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t d
iff
er
en
ce
s 
in
 s
at
is
fa
c‐
tio
n 
w
ith
 d
ec
is
io
n 
m
ak
in
g 
N
o 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t d
iff
er
en
ce
s 
in
 d
ec
is
io
na
l 
co
nf
lic
t,
	q
ua
lit
y	
of
	li
fe
,	t
re
at
m
en
t	
de
ci
si
on
	m
ad
e	
an
d	
pr
ef
er
en
ce
s 
fo
r d
ec
is
io
n 
in
vo
lv
em
en
t 
Pa
tie
nt
 a
nx
ie
ty
 (w
as
 lo
w
 to
 m
od
er
at
e 
at
 a
ll 
tim
e 
po
in
ts
) d
id
 n
ot
 d
iff
er
 b
et
w
ee
n 
st
ud
y 
ar
m
s
G
oo
d
M
od
er
at
e
6
Lu
ng
	c
an
ce
r
D
ec
is
io
n 
bo
ar
d
Ta
ng
 (2
00
8)
 
(T
an
g	
et
	a
l.,
	
20
08
)
U
nr
es
ec
ta
bl
e	
lu
ng
	
ca
nc
er
	p
at
ie
nt
s,
	
af
te
r	
di
ag
no
si
s,
	
n	
=	
92
	(F
:	2
4%
), 
m
ed
ia
n 
ag
e:
 
68
 y
ea
rs
U
nc
on
tr
ol
le
d,
	
ob
se
rv
at
io
na
l 
st
ud
y
Pr
im
ar
y:
 p
at
ie
nt
’s 
pr
ef
er
re
d 
Fr
ac
tio
na
tio
n 
sc
he
du
le
 (1
7 
G
y 
in
 tw
o 
fr
ac
tio
ns
 v
s.
 3
9 
G
y 
in
 1
3 
fr
ac
ti
on
s)
, 
Se
co
nd
ar
y:
 p
at
ie
nt
s’ 
re
as
on
s 
an
d 
th
ei
r l
ev
el
 o
f s
at
is
fa
ct
io
n 
w
ith
 
be
in
g 
in
vo
lv
ed
 in
 th
e 
de
ci
si
on
 
m
ak
in
g 
pr
oc
es
s.
Fi
ft
y‐
on
e	
pa
ti
en
ts
	in
di
ca
te
d	
a	
pr
ef
er
en
ce
	f
or
	3
9	
G
y	
in
 1
3 
fr
ac
tio
ns
 a
nd
 4
1 
ch
os
e 
17
 G
y 
in
 tw
o 
fr
ac
tio
ns
 
af
te
r g
oi
ng
 th
ro
ug
h 
th
e 
de
ci
si
on
 b
oa
rd
 p
ro
ce
ss
 
Lo
ng
er
	F
x	
w
as
	c
ho
se
n	
be
ca
us
e	
of
	lo
ng
er
	s
ur
vi
va
l	
(9
0%
)	a
nd
	b
et
te
r	
lo
ca
l	c
on
tr
ol
	(1
2%
).	
Sh
or
te
r	
Fx
	
w
as
 c
ho
se
n 
fo
r s
ho
rt
er
 o
ve
ra
ll 
tr
ea
tm
en
t d
ur
at
io
n 
(8
0%
),	
co
st
	(6
1%
)	a
nd
	b
et
te
r	
sy
m
pt
om
	c
on
tr
ol
	(2
0%
) 
A
ll	
pa
ti
en
ts
	(1
0
0%
)	w
er
e	
sa
ti
sf
ie
d	
w
it
h	
be
in
g	
in
vo
lv
ed
 in
 th
e 
de
ci
si
on
 m
ak
in
g 
pr
oc
es
s
Fa
ir
V
er
y	
lo
w
5
CH
ES
S
D
uB
en
sk
e 
(2
01
0)
 
(D
uB
en
sk
e 
et
 
al
.,	
20
10
)
N
on
‐s
m
al
l c
el
l l
un
g 
ca
nc
er
, a
ft
er
 d
ia
g‐
no
sis
, n
 =
 2
85
 (F
: 
50
%
), 
m
ed
ia
n 
ag
e:
 
62
 y
ea
rs
RC
T
Pr
im
ar
y:
 p
at
ie
nt
 sy
m
pt
om
 d
is
tr
es
s 
m
ea
su
re
d 
by
 c
ar
eg
iv
er
s
Ca
re
gi
ve
rs
 in
 th
e 
CH
ES
S 
ar
m
 c
on
sis
te
nt
ly
 re
po
rt
ed
 
lo
w
er
 p
at
ie
nt
 p
hy
sic
al
 sy
m
pt
om
 d
is
tr
es
s (
at
 4
 m
on
th
s 
[p
 =
 0
.0
31
; C
oh
en
 d
 =
 0
.4
2]
 a
nd
 a
t 6
 m
on
th
s ]
p 
= 
0.
00
4;
 d
 =
 0
.6
1]
) 
M
ar
gi
na
lly
 si
gn
ifi
ca
nt
 d
iff
er
en
ce
s a
t 2
 m
on
th
s 
(p
 =
 0
.0
51
; d
 =
 0
.3
9)
 a
nd
 a
t 8
 m
on
th
s (
p 
= 
0.
06
1;
 
d 
= 
0.
43
)
Fa
ir
M
od
er
at
e
6 (C
on
tin
ue
s)
     |  7 of 14SPRONK et al.
N
am
e 
of
 d
ec
i-
si
on
 a
id
/s
ho
rt
 
de
sc
rip
tio
n
Fi
rs
t a
ut
ho
r 
(y
ea
r)
St
ud
y 
po
pu
la
tio
n 
n 
(s
ex
), 
ag
e
D
es
ig
n
D
ec
is
io
n 
ai
d 
ou
tc
om
e 
m
ea
su
re
s
O
ut
co
m
e
Q
ua
lit
ya
G
R
A
D
E
IP
D
A
S
N
ot
 lu
ng
 o
r c
ol
or
ec
ta
l c
an
ce
r s
pe
ci
fic
Q
ue
st
io
n 
pr
om
pt
 s
he
et
 
(Q
PS
)
Sh
ira
i (
20
12
) 
(S
hi
ra
i	e
t	
al
.,	
20
12
)
A
dv
an
ce
d	
ca
nc
er
	p
a‐
ti
en
ts
	(l
un
g,
	g
as
tr
ic
,	
co
lo
re
ct
al
,	o
e‐
so
ph
ag
ea
l,	
n	
=	
63
	
(F
:	3
4%
),	
m
ed
ia
n	
ag
e 
64
 y
ea
rs
RC
T
Pr
im
ar
y:
 p
at
ie
nt
 ra
tin
g 
of
 th
e 
us
e‐
fu
ln
es
s 
of
 th
e 
m
at
er
ia
l(s
) 
Se
co
nd
ar
y:
 s
at
is
fa
ct
io
n 
w
ith
 th
e 
co
ns
ul
ta
ti
on
,	n
um
be
r	
of
	q
ue
st
io
ns
	
ov
er
al
l	a
nd
	f
re
qu
en
cy
	o
f	q
ue
st
io
ns
Pa
tie
nt
s 
ga
ve
 a
 g
re
at
er
 u
se
fu
ln
es
s 
sc
or
e 
fo
r t
he
 m
a‐
te
ri
al
s	
(t
o	
as
k	
qu
es
ti
on
s	
[p
	=
	0
.0
33
];	
to
	u
nd
er
st
an
d	
th
e	
tr
ea
tm
en
t	
pl
an
	[p
	=
	0
.0
51
];	
w
ill
in
gn
es
s	
to
	u
se
	
m
at
er
ia
l	i
n	
fu
tu
re
	[p
	=
	0
.0
06
]) 
N
o 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t d
iff
er
en
ce
s 
in
 s
at
is
fa
c‐
tio
n 
w
ith
 th
e 
co
ns
ul
ta
tio
n 
N
o 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t d
iff
er
en
ce
s 
in
 n
um
be
r o
f 
to
ta
l	q
ue
st
io
ns
	a
nd
	f
re
qu
en
cy
	o
f	t
yp
e	
of
	q
ue
st
io
ns
G
oo
d
M
od
er
at
e
3
D
ec
is
io
n 
ai
d 
fo
r 
fi
rs
t‐
,	s
ec
on
d‐
,	
th
ir
d‐
	a
nd
	
fo
ur
th
‐l
in
e	
ch
em
ot
he
ra
py
Sm
ith
 (2
01
1)
 
(S
m
it
h	
et
	a
l.,
	
20
11
)
Pa
tie
nt
s 
w
ith
 
m
et
as
ta
ti
c	
br
ea
st
,	
co
lo
re
ct
al
,	l
un
g,
	o
r	
pr
os
ta
te
	c
an
ce
r, 
n	
=	
27
	(F
:	5
6%
), 
m
ea
n 
ag
e:
 6
3 
ye
ar
s
P
ilo
t	
pr
e‐
te
st
,	
po
st
‐t
es
t	
st
ud
y
Pr
im
ar
y:
 N
um
be
r o
f p
at
ie
nt
s 
w
ho
 
op
t f
or
 fu
ll 
di
sc
lo
su
re
 o
nc
e 
th
ey
 
vi
ew
ed
	t
he
	D
A
 
Se
co
nd
ar
y:
 th
e 
am
ou
nt
 o
f i
nf
or
m
a‐
ti
on
	p
at
ie
nt
s	
ha
ve
	a
bo
ut
	c
ur
e,
	
re
sp
on
se
	r
at
es
,	a
nd
	s
ym
pt
om
	
co
nt
ro
l; 
th
e 
im
pa
ct
 o
f t
ru
th
fu
l 
in
fo
rm
at
io
n	
on
	h
op
e,
	w
he
th
er
	t
he
	
in
fo
rm
at
io
n 
w
as
 d
ee
m
ed
 h
el
pf
ul
 
to
 th
e 
pa
tie
nt
; a
nd
 w
he
th
er
 th
e 
pa
tie
nt
 w
an
ts
 to
 s
ha
re
 th
e 
in
fo
r‐
m
at
io
n 
w
ith
 a
 p
hy
si
ci
an
96
%
	(2
6/
27
)	o
f	t
he
	p
at
ie
nt
s	
ch
os
e	
to
	c
om
pl
et
e	
th
e	
D
A
 
Th
e 
pr
op
or
tio
n 
of
 p
at
ie
nt
s 
w
ho
 th
ou
gh
t t
ha
t 
ad
va
nc
ed
	c
an
ce
r	
co
ul
d	
be
	c
ur
ed
	r
ed
uc
ed
	f
ro
m
	5
2%
	
to
	3
2%
	(p
	=
	0
.1
5)
 
Pa
tie
nt
s 
be
ca
m
e 
on
ly
 s
lig
ht
ly
 le
ss
 o
ve
ro
pt
im
is
tic
 
ab
ou
t r
es
po
ns
e 
ra
te
 a
nd
 s
ym
pt
om
 c
on
tr
ol
 (n
ot
 
si
gn
ifi
ca
nt
) 
N
o 
di
st
re
ss
 w
as
 n
ot
ed
 a
nd
 h
op
e 
di
d 
no
t c
ha
ng
e 
93
%
	f
ou
nd
	t
he
	in
fo
rm
at
io
n	
he
lp
fu
l 
74
%
	w
an
te
d	
to
	s
ha
re
	t
he
	in
fo
rm
at
io
n	
w
it
h	
th
ei
r	
fa
m
ily
 a
nd
 p
hy
si
ci
an
Fa
ir
V
er
y	
lo
w
1
CO
N
N
EC
T
M
er
op
ol
 (2
01
3)
 
(M
er
op
ol
	e
t	
al
.,	
20
13
)
M
et
as
ta
tic
 c
an
ce
r 
pa
tie
nt
s, 
n 
= 
62
9,
 (F
: 4
8%
), 
m
ea
n 
ag
e:
 5
9 
ye
ar
s
RC
T 
w
ith
 3
 a
rm
s 
(1
 c
on
tr
ol
, 2
 
in
te
rv
en
tio
n)
b
Tr
ea
tm
en
t o
ut
co
m
e 
ex
pe
ct
at
io
ns
, 
de
ci
sio
na
l c
on
fli
ct
, p
at
ie
nt
 sa
tis
fa
c‐
tio
n 
w
ith
 th
e 
co
nt
en
t a
nd
 fo
rm
at
 o
f 
th
e 
co
m
m
un
ic
at
io
n,
 a
nd
 sa
tis
fa
ct
io
n 
w
ith
 th
e 
su
rv
ey
 a
nd
/o
r c
om
m
un
ic
a‐
tio
n 
sk
ill
s t
ra
in
in
gc
Pa
tie
nt
s w
er
e 
le
ss
 li
ke
ly
 to
 b
el
ie
ve
 th
at
 th
ey
 w
ou
ld
 e
xp
e‐
rie
nc
e 
se
ve
re
 si
de
 e
ff
ec
ts
 w
ith
 st
an
da
rd
 o
r e
xp
er
im
en
‐
ta
l t
he
ra
py
 (p
 <
 0
.0
5)
 
Tr
ea
tm
en
t d
ec
isi
on
s w
er
e 
ea
sie
r t
o 
re
ac
h 
(p
 =
 0
.0
03
) 
Pa
tie
nt
s w
er
e 
m
or
e 
sa
tis
fie
d 
w
ith
 d
ec
isi
on
s (
p 
< 
0.
00
1)
 
Pa
tie
nt
s w
er
e 
m
or
e 
sa
tis
fie
d 
w
ith
 th
e 
ph
ys
ic
ia
n 
co
m
‐
m
un
ic
at
io
n 
fo
rm
at
 (p
 =
 0
.0
26
) 
Pa
tie
nt
s w
er
e 
m
or
e 
sa
tis
fie
d 
w
ith
 th
e 
di
sc
us
sio
n 
re
ga
rd
in
g 
su
pp
or
t s
er
vi
ce
s (
p 
= 
0.
02
9)
 a
nd
 q
ua
lit
y 
of
 
lif
e 
co
nc
er
ns
 (p
 =
 0
.0
42
) 
N
o 
st
at
is
tic
al
ly
 si
gn
ifi
ca
nt
 d
iff
er
en
ce
s i
n 
sa
tis
fa
ct
io
n 
re
ga
rd
in
g 
di
sc
us
sio
n 
of
 d
ia
gn
os
is/
pr
og
no
sis
, t
re
at
m
en
t 
op
tio
ns
, s
up
po
rt
/c
om
m
un
ity
 se
rv
ic
es
, a
nd
 d
ec
isi
on
al
 
co
nf
lic
t s
co
re
s
G
oo
d
Lo
w
7
N
ot
e:
 T
oo
ls
 th
at
 a
re
 n
o 
lo
ng
er
 a
va
ila
bl
e 
ar
e 
pr
in
te
d 
in
 it
al
ic
s.
St
ud
y 
po
pu
la
tio
n:
 n
	=
	s
am
pl
e	
si
ze
;	F
	=
	f
em
al
e.
a A
ss
es
se
d	
w
it
h	
th
e	
qu
al
it
y	
as
se
ss
m
en
t	
to
ol
	o
f	H
aw
ke
r	
et
	a
l.	
(2
0
02
).	
b T
he
	f
in
al
	a
na
ly
si
s	
w
as
	o
n	
tw
o	
ar
m
s:
	(1
)	c
on
tr
ol
	g
ro
up
	(2
)	C
O
N
N
EC
T	
w
it
h	
ph
ys
ic
ia
n	
su
m
m
ar
y	
&
	C
O
N
N
EC
T	
w
it
ho
ut
	p
hy
si
ci
an
	s
um
m
ar
y.
	
c M
ea
su
re
s	
an
d	
ou
tc
om
es
	d
es
cr
ib
ed
	a
s	
in
	t
he
	a
rt
ic
le
.	P
le
as
e	
no
te
	t
ha
t	
th
e	
ov
er
la
p	
is
	n
ot
	c
om
pl
et
e.
	
T
A
B
L
E
 2
 
(C
on
tin
ue
d)
8 of 14  |     SPRONK et al.
advanced	colorectal	cancer	patients.	It	was,	however,	not	evaluated	
in this patient group.
3.2 | Lung cancer DAs
Three	of	the	four	DAs	identified	for	advanced	lung	cancer	are	still	
available.	One	DA	consisted	of	a	website	that	 is	still	being	devel‐
oped	 and	 that	 describes	 characteristics,	 side	 effects	 and	 differ‐
ences between surgery and radiotherapy; it assists patients in 
thinking about their preferences and values to let them make an in‐
formed	decision	(MAASTRO	clinic,	2018).	A	second	DA	comprised	
a	decision	board	(Tang	et	al.,	2008)	about	the	advantages	and	dis‐
advantages	of	various	radiation	schedules.	Lastly,	the	third	DA	con‐
sisted of a booklet for stage 4 lung cancer patients (Steendam et 
al.,	2016)	about	the	potential	treatment	options	(including	chemo‐
therapy,	immunotherapy	and	experimental	studies)	versus	support‐
ive	 care	without	 anti‐cancer	 therapy.	The	DA	of	DuBenske	et	 al.	
(2010)	(CHESS)	is	no	longer	available.	This	DA	comprised	an	inter‐
active communication system to bridge the communication gaps 
that	occur	between	patients,	families	and	clinicians	in	cancer	care	
in	order	to	enhance	SDM.
The	 effectiveness	 of	 two	 out	 of	 the	 four	 DAs	 was	 tested	
(DuBenske	 et	 al.,	 2010;	 Tang	 et	 al.,	 2008),	 although	 they	 differed	
substantially	 in	 terms	of	 study	design,	 content	 and	outcome	mea‐
sures.	The	CHESS	DA	(DuBenske	et	al.,	2010)	was	tested	in	an	RCT	
and compared against a control group that received standard care 
and	had	access	to	the	Internet.	Using	CHESS	resulted	in	significantly	
lower distress in patients (p	=	0.031;	quality:	fair,	GRADE:	moderate,	
IPDAS:	6/7).	The	decision	board	(Tang	et	al.,	2008)	was	tested	in	an	
observational study with a suboptimal design that had no control 
group and in which the description of the outcome measures was 
deficient.	Evaluation	showed	that	all	patients	(100%)	were	satisfied	
with	 being	 involved	 in	 the	 decision	 making	 process	 (quality:	 fair,	
GRADE:	very	low,	IPDAS:	5/7).
3.3 | Generic DAs used by colorectal and lung 
cancer patients
The	four	other	DAs	were	generic	for	all	cancer	types	but	were	used	
in advanced colorectal and/or lung cancer patients. Three of these 
are	still	available.	The	first	DA	is	a	communication	aid	(Shirai	et	al.,	
2012)	that	includes	a	question	prompt	sheet	that	can	be	used	by	pa‐
tients	during	a	consultation.	The	other	two	DAs	consist	of	a	booklet	
with	either	sample	questions	accompanied	by	an	instrument	about	
value	 clarification	 (currently	 being	 evaluated)	 (Henselmans	 et	 al.,	
2018)	 or	 a	 booklet	 with	 tables	 including	 information	 about	 first‐,	
second‐,	 third‐	 and	 fourth‐line	 chemotherapy	 (Smith	 et	 al.,	 2011).	
The	CONNECT	DA	(Meropol	et	al.,	2013)	is	not	available	anymore.	
This	DA	was	 a	 communication	 aid	 for	 patients	 and	 assessed	 their	
values,	goals	and	communication	preferences,	alongside	communi‐
cation	skills	training.	This	was	the	only	DA	identified	that	engaged	
the healthcare provider by providing them with a summary report of 
the patient's responses.
Three	of	the	generic	DAs	were	evaluated.	Two	were	tested	in	an	
RCT	comparing	 them	against	 standard	 care	 (Meropol	 et	 al.,	 2013;	
Shirai	et	al.,	2012),	and	one	was	tested	in	a	pilot	study	without	a	con‐
trol	group	but	with	a	pre‐test/post‐test	design	(Smith	et	al.,	2011).	
The	DA	of	Meropol	et	al.	significantly	increased	patient	satisfaction,	
while making it easier to reach decisions compared to standard care 
(quality:	good,	GRADE:	low,	IPDAS	7/7).	Patients	rated	the	materials	
of	the	DA	of	Shirai	et	al.	(2012)	as	useful,	but	the	DA	did	not	lead	to	
statistically	 significant	differences	 in	 the	overall	numbers	of	ques‐
tions	posed	and	the	frequency	of	questions	compared	to	standard	
care	 (quality:	 good,	GRADE:	moderate,	 IPDAS:	 3/7).	 The	 informa‐
tion	tables	(Smith	et	al.,	2011)	were	felt	to	be	helpful	(74%).	Patients	
were	willing	 to	 complete	 the	DA	 (96%)	 and	 share	 the	 information	
with	 their	physician	 (93%),	which	might	 result	 in	SDM.	That	being	
said,	31%	of	the	patients	thought	that	their	cancer	could	be	cured	
and	87%	overestimated	the	positive	effects	of	palliative	chemother‐
apy	(quality:	fair,	GRADE:	very	low,	IPDAS:	1/7).
4  | DISCUSSION
The	aim	of	this	systematic	review	was	to	provide	an	overview	of	DAs	
for patients with advanced colorectal or lung cancer and to assess 
their	availability	and	effectiveness.	This	is	a	highly	under‐researched	
area,	despite	patients	facing	multiple	preference‐sensitive	decisions	
affecting	survival	time	and	quality	of	life.	Twelve	DAs	were	identi‐
fied	(evenly	distributed	between	colorectal,	lung	and	generic	cancer	
DAs),	of	which	10	are	still	available.	Only	seven	of	the	DAs	have	been	
evaluated,	and	the	effectiveness	on	patient	outcomes	was	 limited.	
Moreover,	the	quality	of	the	DAs	and	the	evidence	was	impaired	(low	
to	moderate)	due	to	many	forms	of	biases,	limiting	the	certainty	with	
which	firm	conclusions	can	be	drawn	about	the	DAs’	effectiveness.
Our systematic review first illustrates that there is a lack of read‐
ily	available	DAs	for	use	in	advanced	colorectal	and	lung	cancer	care.	
This is in contrast to the earlier phases of the cancer pathway. In a 
systematic	review,	conducted	in	2014,	55	available	DAs—across	var‐
ious	cancer	types—were	found	(Trikalinos,	Wieland,	Adam,	Zgodic,	
&	Ntzani,	2014).	Of	the	10	available	tools	that	were	identified,	some	
were	 still	 in	 the	development	or	 testing	phase	 (Henselmans	et	 al.,	
2018;	MAASTRO	clinic,	2018)	and	another	was	over	a	decade	old	
and	no	update	seems	to	have	occurred	(Tang	et	al.,	2008).	Whether	
or not the other tools were updated after publication remains un‐
clear.	This	might	be	problematic,	as	guidelines	change	over	time	and	
more evidence about the recommended treatment of choice may 
become	available.	Moreover,	two	of	the	DAs	that	improved	patient	
outcomes	such	as	physical	distress	(DuBenske	et	al.,	2010)	and	de‐
cision	 making/communication	 satisfaction	 (Meropol	 et	 al.,	 2013)	
were	no	 longer	available	due	to	a	 lack	of	funding	to	keep	the	DAs	
available and up to date (personal communication). These results are 
in	 line	with	 two	 related,	 recently	 published	 systematic	 reviews	 of	
DAs	in	advanced	breast	and	other	cancers	(Spronk,	Burgers,	et	al.,	
2018;	 Tapp	&	Blais,	 2018),	which	 also	 found	 few	 available,	 up‐to‐
date	DAs.	For	example,	 four	out	of	 the	 sixteen	 identified	DAs	 for	
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advanced cancer had not been updated in the last 15 years (Tapp & 
Blais,	2018).	This	seem	to	contrast	with	the	push	from	many	govern‐
ments	to	endorse	the	use	of	DAs	to	improve	clinical	SDM	and	the	
quality	of	care	provided	(Australian	Commission	on	Safety	Quality	
in	Health	Care,	2015;	Department	of	Health,	2010;	Saskatchewan	
Health	Quality	Council,	2009;	United	States	Federal	Statute,	2010).
Before	the	clinical	use	of	DAs	can	be	widely	recommended	for	
patients	with	advanced	colorectal	and	lung	cancer,	it	is	essential	that	
they have demonstrated the ability to improve patient outcomes. 
Our	systematic	review	provided	little	unequivocal	evidence	that	this	
is the case in advanced colorectal and lung cancer patients. Some 
positive	effects	were	found,	 for	example	on	subjective	knowledge	
(Oostendorp	 et	 al.,	 2017),	 prognostic	 understanding	 (Leighl	 et	 al.,	
2011),	 and	 satisfaction	 with	 communication	 and	 decision	 making	
(Meropol	et	al.,	2013).	Many	of	the	outcomes	studied,	however,	re‐
mained	unaffected	and	the	quality	of	the	evidence	was	suboptimal,	
making it difficult to draw firm conclusions. These limitations hold for 
many	DAs	in	advanced	cancer,	as	similar	conclusions	were	reached	
by	the	above‐mentioned	systematic	reviews	(Spronk,	Burgers,	et	al.,	
2018;	Tapp	&	Blais,	2018).
While	the	aim	of	DAs	is	to	improve	patient	outcomes,	it	is	equally	
important to ascertain that their use is not harmful. We found that 
the	DAs	 included	 did	 not	 increase	 patients’	 psychological	 distress	
(e.g.,	anxiety	(Leighl	et	al.,	2011;	Oostendorp	et	al.,	2017))	or	diminish	
patients’	hope	(Smith	et	al.,	2011).	These	findings	illustrate	that	cli‐
nicians	might	not	need	to	worry	that	using	DAs	will	negatively	affect	
their	patients’	well‐being,	but	should	also	not	be	too	optimistic	that	
it improves their outcomes. These findings are in line with a recent 
updated	Cochrane	review	of	SDM	initiatives,	in	which	uncertain	evi‐
dence	from	available	DAs	and	related	tools	on	patient	outcomes	was	
found.	(Légaré	et	al.,	2018).	This	underlines	the	need	for	more	high‐
quality	studies	in	this	quickly	evolving	research	field	to	guide	clinical	
practice and policy further.
Several recommendations can be made for optimising the de‐
velopment	 and	 evaluation	 of	 current	 and	 future	DAs	 in	 advanced	
colorectal	and	lung	cancer	care.	First,	improvements	of	current	DAs	
and	development	of	future	DAs	should	preferably	be	done	in	collab‐
oration with national and international medical and physicians’ as‐
sociations,	which	also	take	ownership	and	responsibility	for	keeping	
the	DAs	up	 to	 date.	Using	 the	best	 available	 evidence	 and	 guide‐
lines	(like	IPDAS)	to	provide	information	for	the	development	phase	
should	also	improve	the	quality	of	DAs	(Durand	et	al.,	2015;	Elwyn	
et	 al.,	 2006;	 Joseph‐Williams	 et	 al.,	 2014).	 Second,	 it	 is	 essential	
to	understand	whether	DAs	 improve	SDM	 in	clinical	practice,	and	
subsequently	patient	outcomes.	Only	few	current	studies	assessed	
whether	DAs	actually	 improve	SDM	(Stacey	et	al.,	2017).	Previous	
studies	showed	that	DAs	used	by	patients	before	the	consultation	
often	lead	to	a	better	understanding	of	the	options,	but	do	not	guar‐
antee	SDM	 (Hargraves	&	Montori,	 2014;	Stiggelbout	et	 al.,	 2012).	
Focusing	on	the	link	between	SDM	and	patient	outcomes,	SDM	in	
colorectal or lung cancer (irrespective of patients’ preferences for 
SDM)	 improves	 the	 evaluated	 quality	 of	 received	 communication	
and	provided	care	from	the	patient's	perspective	(Kehl	et	al.,	2015).	
In	 other	 settings,	 tools	 (e.g.,	 Option	 Grids)	 have	 been	 developed	
that can be used by the patient and clinician together during a clin‐
ical	visit	to	ensure	SDM	and	to	improve	patient	outcomes	(Breslin,	
Mullan,	&	Montori,	2008;	Elwyn	et	al.,	2013).	Such	tools	might	be	
useful	 for	 improving	 SDM	and	patient	 outcomes	 in	 advanced	 col‐
orectal	 and	 lung	 cancer	 care.	 Third,	 according	 to	 an	 expert	 group	
of	 clinicians,	 researchers	 and	 patient	 representatives	 (Spronk,	 van	
Dulmen,	Heins,	&	van	Vliet,	2018),	several	preconditions	at	the	level	
of	the	organisation	(e.g.,	enough	time	(Legare	et	al.,	2008),	profes‐
sional	 (e.g.,	 a	perceived	added	value	of	SDM),	patient	 (e.g.,	 insight	
into	options)	and	patient–clinician	interaction	(continuous	check	of	
patient	preferences)	need	to	be	met	in	order	for	SDM	initiatives	such	
as	DAs	to	be	successful	(van	Vliet	et	al.,	2018).	Fourth,	patients	and	
patient associations need to be involved from development through 
to	 implementation	 in	order	 to	ensure	 the	DA	 is	useful	 and	under‐
standable	(Montori,	Breslin,	Maleska,	&	Weymiller,	2007).
4.1 | Strengths and limitations
This	review	has	strengths	and	limitations.	A	strength	is	the	compre‐
hensive	 overview,	 including	 all	 languages	 and	 the	 fact	 that	 a	 sys‐
tematic literature search was conducted alongside an Internet and 
expert inventory. Four medical and social science databases were 
searched using a systematic search strategy that was developed 
in collaboration with an experienced librarian and checked by an 
expert	 in	the	field.	A	 limitation	 is	 that	only	some	of	the	DAs	were	
evaluated and that we did not assess patients’ and clinicians’ views 
on	the	included	DAs.	In	addition,	the	title/abstract	screening	of	our	
systematic	 review	 was	 predominantly	 (85%)	 done	 by	 a	 single	 re‐
searcher,	which	could	potentially	have	led	to	studies	being	missed.	
However,	in	the	case	of	any	doubt	during	the	title/abstract	screen‐
ing,	the	record	was	included	and	screened	by	two	authors	indepen‐
dently	during	full‐text	screening.	Manual	searches	of	the	reference	
lists of articles included were conducted in order to identify poten‐
tially	missed	relevant	studies.	Limitations	at	the	study	level	include	
the	generally	low	quality	of	evidence	of	the	DAs	included,	which	was	
due	to	multiple	sources	of	bias	(e.g.,	study	design,	small	sample	sizes,	
high	drop‐out	rates,	presentation	of	selective	results).	This	may	have	
skewed	 the	 results.	 Limitations	 at	 the	 outcome	 level	 include	 the	
various outcome measures across studies that impeded comparison 
of	DAs	at	the	outcome	level.	Finally,	we	primarily	consulted	Dutch	
experts,	which	may	have	caused	bias	in	the	identification	of	unpub‐
lished work.
5  | CONCLUSION
To	conclude,	there	is	a	shortage	of	readily	available	DAs	with	dem‐
onstrated positive effects on patient outcomes in advanced colo‐
rectal or lung cancer. Rigorous testing is needed of the effects of 
DAs	that	have	not	yet	been	tested	in	proper	designs	(possibly	after	
updating),	DAs	that	are	currently	under	development,	and	DAs	that	
may be developed in the future. Such initiatives are urgently needed 
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in	order	to	inform	and	shape	the	worldwide	focus	on	using	DAs	and	
improving	SDM	in	clinical	care	and	to	ensure	patient	outcomes	are	
improved.
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APPENDIX 1
SE ARCH S TR ATEGY
Search	in	Pubmed	(date:	16	March	2018)
Search strategy Number of hits
Colorectal cancer
#1 "colorectal	cancer"[tiab]
#2 colorectal	neoplasms[mesh]
#3 "colon	cancer"[tiab]
#4 "rectal	cancer"[tiab]
#5 "rectum	cancer"[tiab]
#6 "adenoma	cancer"[tiab]
Lung	cancer
#7 "lung	cancer"[tiab]
#8 "non‐small	cell	lung	cancer"[tiab]
#9 "non	small	cell	lung	cancer"[tiab]
#10 "small	cell	lung	cancer"[tiab]
#11 lung	neoplasms[mesh]
#12 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR # #10 OR #11 446,543
Advanced	care
#13 palliative	care[mesh]
#14 palliative[tiab]
#15 Hospice	Care[mesh]
#16 hospice[tiab]
#17 end‐of‐life[tiab]
#18 terminal[tiab]
#19 incurable[tiab]
#20 Terminal	Care[mesh]
#21 "early	palliative	care"[tiab]
#22 "serious	illness"[tiab]
#23 "advanced	cancer"[tiab]
#24 "metastatic	cancer"[tiab]
#25 metastasis[tiab]
#26 Neoplasm	Metastasis[MeSH	Terms]
(Continues)
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Search strategy Number of hits
#27 #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR 
#25 OR #26
816,032
Decision making
#28 "decision	making"[tiab]
#29 "decision	support"[tiab]
#30 "decision	aid*"[tiab]
#31 "choice	behavior"[tiab]
#32 "choice	behaviour"[tiab]
#33 (((((shared)[tiab]	OR	sharing)[tiab]	OR	informed[tiab])))	AND	((decision*[tiab])	OR	choice*[tiab])
#34 #28 OR #29 OR #30 OR #31 OR #32 OR #33 131,245
#35 #12	AND	#27	AND	#34 512
limit	#35	to	(humans	and	yr="2006–2017") 397
Note:	This	initial	search	strategy	was	adapted	to	Cinahl,	Medline	and	PsychInfo.
APPENDIX 2
INTERNE T SE ARCH
Internet	search	in	Google	(date:	21	March	2018).
Internet search Number of hits
Search 1
#1 Shared decision making
#2 Lung	cancer
#3 Colorectal cancer
#1	AND	(#2	OR	#3) 26,100,000
Search 2
#4 Decision aid
#5 Lung	cancer
#6 Colorectal cancer
#4	AND	(#5	OR	#6) 8,870,000
Search 3
#7 Decision support
#8 Lung	cancer
#9 Colorectal cancer
#7	AND	(#8	OR	#9) 26,900,000
Search 4
#10 Shared decision making
#11 Decision aid
#12 Decision support
#13 Advanced	cancer
#14 Palliative cancer care
(#10	OR	#11	OR	#12)	AND	(#13	OR	#14) 4,310,000
APPENDIX 1 (Continued)
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